PMID- 35784288
OWN - NLM
STAT- MEDLINE
DCOM- 20220706
LR  - 20220716
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in 
      Patients With Rheumatoid Arthritis.
PG  - 823669
LID - 10.3389/fimmu.2022.823669 [doi]
LID - 823669
AB  - The clinical features of rheumatoid arthritis (RA)-associated interstitial lung 
      disease (ILD) (RA-ILD) usually manifest to an advanced stage of lung disease, 
      which leads the challenge of early diagnosis and the difficulty in guiding 
      treatments for patients with RA-ILD in clinical settings. The aim of this study 
      was to construct a nomogram for identifying ILD in RA patients. Through the 
      incorporation of the level of matrix metalloproteinase-3 (MMP-3) in plasma, 
      demographics, clinical feature, and laboratory parameters of 223 RA patients (85 
      RA-ILD) which were grouped as training cohorts and validation cohorts, an 
      identifying nomogram of RA-ILD was built. Candidate variables for the nomogram 
      were screened using univariable analysis and multivariable logistic regression 
      analysis. The accuracy of the diagnostic nomogram was measured via concordance 
      index (C-index), calibration plots, and decision curve analysis (DCA). Results 
      showed that plasma MMP-3 protein was elevated in RA-ILD patients compared with 
      non-ILD RA patients in both training cohorts (p = 0.0475) and validation cohorts 
      (p = 0.0006). Following a final regression analysis, the gender of male, current 
      smoking state, levels of circulating rheumatoid factor (RF), C-reactive protein 
      (CRP), and MMP-3 were identified as risk factors for the construction of the 
      nomogram. The calibration plots further showed a favorable consistency between 
      the identifying nomogram and actual clinical findings. In consistence, the 
      C-index (0.826 for both training cohorts and validation cohorts) indicated the 
      satisfactory discriminative ability of the nomogram. Although the incorporation 
      of MMP-3 failed to significantly improve identified outcomes of the nomogram as 
      determined by DCA, including the level of circulating MMP-3 increased the 
      diagnostic accuracy of the nomogram for ILD in RA patients. Thus, our proposed 
      model can serve as a non-invasive tool to identify ILD in RA patients, which may 
      assist physicians to make treatment decisions for RA patients.
CI  - Copyright (c) 2022 Xue, Hu, Wu, Wang, Chi and Liu.
FAU - Xue, Jing
AU  - Xue J
AD  - Key Laboratory of Ministry of Education for Conservation and Utilization of 
      Special Biological Resources in the Western, College of Life Science, Ningxia 
      University, Yinchuan, China.
AD  - Ningxia Key Laboratory of Stem Cell and Regenerative Medicine, General Hospital 
      of Ningxia Medical University, Yinchuan, China.
FAU - Hu, Wenfeng
AU  - Hu W
AD  - Key Laboratory of Ministry of Education for Conservation and Utilization of 
      Special Biological Resources in the Western, College of Life Science, Ningxia 
      University, Yinchuan, China.
FAU - Wu, Shuang
AU  - Wu S
AD  - Key Laboratory of Ministry of Education for Conservation and Utilization of 
      Special Biological Resources in the Western, College of Life Science, Ningxia 
      University, Yinchuan, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Pathology, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Chi, Shuhong
AU  - Chi S
AD  - Department of Rheumatology, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Liu, Xiaoming
AU  - Liu X
AD  - Key Laboratory of Ministry of Education for Conservation and Utilization of 
      Special Biological Resources in the Western, College of Life Science, Ningxia 
      University, Yinchuan, China.
AD  - Department of Anatomy and Cell Biology, Carver College of Medicine, the 
      University of Iowa, Iowa City, IA, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220616
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Blood Proteins)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - *Arthritis, Rheumatoid/complications/diagnosis
MH  - Blood Proteins
MH  - C-Reactive Protein
MH  - Humans
MH  - *Lung Diseases, Interstitial/diagnosis/etiology
MH  - Male
MH  - Matrix Metalloproteinase 3
MH  - Nomograms
MH  - Rheumatoid Factor
PMC - PMC9245420
OTO - NOTNLM
OT  - interstitial lung disease
OT  - matrix metalloproteinase-3
OT  - nomogram
OT  - rheumatoid arthritis
OT  - risk factors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/07 06:00
PMCR- 2022/01/01
CRDT- 2022/07/05 10:22
PHST- 2021/11/27 00:00 [received]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/07/05 10:22 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.823669 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jun 16;13:823669. doi: 10.3389/fimmu.2022.823669. eCollection 
      2022.